Lexicon Pharmaceuticals, Inc.

LXRX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$200-$177-$102-$88
Dep. & Amort.$1$1$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$13$14$12$11
Change in WC$14$3$0-$10
Other Non-Cash-$7-$2$1$0
Operating Cash Flow-$179-$162-$89-$87
Investing Activities
PP&E Inv.-$1-$0-$1-$1
Net Acquisitions$0$0$70-$3
Inv. Purchases-$338-$223-$134-$34
Inv. Sales/Matur.$314$174$64$38
Other Inv. Act.$9$0-$70$3
Investing Cash Flow-$15-$50-$71$2
Financing Activities
Debt Repay.$0$50$49-$12
Stock Issued$0$139$94$37
Stock Repurch.-$2-$1-$1-$3
Dividends Paid$0$0$0$0
Other Fin. Act.$240$0$0$0
Financing Cash Flow$238$188$142$23
Forex Effect$0$0$0$0
Net Chg. in Cash$44-$24-$18-$62
Supplemental Information
Beg. Cash$22$46$64$126
End Cash$67$22$46$64
Free Cash Flow-$180-$162-$90-$88
Lexicon Pharmaceuticals, Inc. (LXRX) Financial Statements & Key Stats | AlphaPilot